Table 1.

Conventional or dose-intensified induction/consolidation ± rituximab in newly diagnosed mantle cell lymphoma.

AuthorstudynInductionconsolidationResponse rate OR (CR)Median PFS/EFSMedian OS
*Only relapsed disease. 
CHOP indicates cyclophosphamide, doxorubicin, vincristine, and prednisone; FCM, fladarabine, cyclophosphamide, mitoxantrone; HyperCVAD/MA, fractionated cyclophosphamide, doxorubicin, vincristine, dexamethasone; alternated with high-dose methotrexate and cytarabine; PR, partial response rate; CR, complete response rate; PFS, progression-free survival; TTF, time to treatment failure; FFS, failure free survival; EFS, event-free survival; OS, overall survival; ASCT, autologous stem cell transplantation. 
Herold 200820  Phase III 90 Conventional (MCP) IFN 63% (15%) 18 mo 56 mo 
   Conventional (R-MCP) IFN 71% (32%) 20 mo 50 mo 
Howard 200210  Phase II 40 Conventional (R-CHOP) — 96% (CR/Cru: 48 %) 16.6 mo n.a. 
Lenz 2005,21  Phase III 123 Conventional (R-CHOP) IFN maintenance 94% (34%) 28 mo (TTF) 59% (5 y) 
Hoster 200857    Conventional (CHOP) vs ASCT 75% (7%) 14 months (TTF) 46% (5 y) 
Rummel 200823  Phase III 88 Conventional (R-CHOP) — 95% (35%) n.a. n.a. 
   Conventional (R-bendamustine) — 89% (32%) n.a. n.a. 
Dreyling 200824  Phase III 75 Conventional (CHOP/MCP) Intensive (ASCT) 78% (42%) 43 months 90 months 
Dreger 200725  Phase II 34 Conventional (CHOP/->R) Intensive (ASCT) 88% (24%) 83% (4 y) 87% (4 y) 
LeFrere 200419  Phase II 28 Conventional (CHOP/DHAP) Intensive (ASCT) 89% (82%) 51 months 81 months 
de Guibert 200626  Phase II 24 Conventional (R-DHAP) Intensive (ASCT) 96% (92%) 65% (3 y) 69% (3 y) 
Delarue 200927  Phase II 60 Conventional (R-CHOP/R-DHAP) Intensive (ASCT) 95% (96%) 83 mo 75% (5 y) 
Dreyling 200828  Phase III 390 Conventional (R-CHOP) Intensive (ASCT) 91% (51%) 84% (2 y) 77% (2 y) 
   Conventional (R-CHOP/R-DHAP) Intensive (ASCT)    
Romaguera 200529  Phase II 97 Intensive (R-Hyper-CVAD/MA) — 97% (CR/CRu: 87%) 54 mo 82 % (3 y) 
Epner 200730  Phase II 97 Intensive (R-Hyper-CVAD/MA) — 88% (CR/CRu: 58%) 64% (2 y) 74% (3 y) 
Magni 200931  Phase II 28 R-High dose Cyclo, Ara-C, Melphalan, Mitoxantrone Intensive (ASCT) 96% (96%) 48% in low risk; 34% in high risk 76% in low risk; 68% in high risk 
Tam 2009*32  Phase II 42 Intensive (R-Hyper-CVAD/MA) Intensive (ASCT) 96% (CR/Cru: 96%) 42 mo 93 mo 
  7 Conventional (R-CHOP)     
Ritchie 200733  Phase II 13 Intensive (R-Hyper-CVAD/MA) Intensive (ASCT) 100% (92%) 92% (3 y) 92% (3 y) 
Till 200834  Phase II 21 Intensive (R-Hyper-CVAD/MA) Intensive (ASCT) 100% (CR/CRu: 81%) 81% (3 y) 94% (3 y) 
Vose 200635  Phase II 32 Intensive (R-Hyper-CVAD/MA) Intensive (ASCT) 100% (CR/CRu: 81%) 78% (3 y) 97% (3 y) 
Geissler 2008 36  Phase II 159 Intensive (R-CHOP-HA) Intensive (ASCT) 96% (55%) 63% (4 y) 81% (4 y) 
AuthorstudynInductionconsolidationResponse rate OR (CR)Median PFS/EFSMedian OS
*Only relapsed disease. 
CHOP indicates cyclophosphamide, doxorubicin, vincristine, and prednisone; FCM, fladarabine, cyclophosphamide, mitoxantrone; HyperCVAD/MA, fractionated cyclophosphamide, doxorubicin, vincristine, dexamethasone; alternated with high-dose methotrexate and cytarabine; PR, partial response rate; CR, complete response rate; PFS, progression-free survival; TTF, time to treatment failure; FFS, failure free survival; EFS, event-free survival; OS, overall survival; ASCT, autologous stem cell transplantation. 
Herold 200820  Phase III 90 Conventional (MCP) IFN 63% (15%) 18 mo 56 mo 
   Conventional (R-MCP) IFN 71% (32%) 20 mo 50 mo 
Howard 200210  Phase II 40 Conventional (R-CHOP) — 96% (CR/Cru: 48 %) 16.6 mo n.a. 
Lenz 2005,21  Phase III 123 Conventional (R-CHOP) IFN maintenance 94% (34%) 28 mo (TTF) 59% (5 y) 
Hoster 200857    Conventional (CHOP) vs ASCT 75% (7%) 14 months (TTF) 46% (5 y) 
Rummel 200823  Phase III 88 Conventional (R-CHOP) — 95% (35%) n.a. n.a. 
   Conventional (R-bendamustine) — 89% (32%) n.a. n.a. 
Dreyling 200824  Phase III 75 Conventional (CHOP/MCP) Intensive (ASCT) 78% (42%) 43 months 90 months 
Dreger 200725  Phase II 34 Conventional (CHOP/->R) Intensive (ASCT) 88% (24%) 83% (4 y) 87% (4 y) 
LeFrere 200419  Phase II 28 Conventional (CHOP/DHAP) Intensive (ASCT) 89% (82%) 51 months 81 months 
de Guibert 200626  Phase II 24 Conventional (R-DHAP) Intensive (ASCT) 96% (92%) 65% (3 y) 69% (3 y) 
Delarue 200927  Phase II 60 Conventional (R-CHOP/R-DHAP) Intensive (ASCT) 95% (96%) 83 mo 75% (5 y) 
Dreyling 200828  Phase III 390 Conventional (R-CHOP) Intensive (ASCT) 91% (51%) 84% (2 y) 77% (2 y) 
   Conventional (R-CHOP/R-DHAP) Intensive (ASCT)    
Romaguera 200529  Phase II 97 Intensive (R-Hyper-CVAD/MA) — 97% (CR/CRu: 87%) 54 mo 82 % (3 y) 
Epner 200730  Phase II 97 Intensive (R-Hyper-CVAD/MA) — 88% (CR/CRu: 58%) 64% (2 y) 74% (3 y) 
Magni 200931  Phase II 28 R-High dose Cyclo, Ara-C, Melphalan, Mitoxantrone Intensive (ASCT) 96% (96%) 48% in low risk; 34% in high risk 76% in low risk; 68% in high risk 
Tam 2009*32  Phase II 42 Intensive (R-Hyper-CVAD/MA) Intensive (ASCT) 96% (CR/Cru: 96%) 42 mo 93 mo 
  7 Conventional (R-CHOP)     
Ritchie 200733  Phase II 13 Intensive (R-Hyper-CVAD/MA) Intensive (ASCT) 100% (92%) 92% (3 y) 92% (3 y) 
Till 200834  Phase II 21 Intensive (R-Hyper-CVAD/MA) Intensive (ASCT) 100% (CR/CRu: 81%) 81% (3 y) 94% (3 y) 
Vose 200635  Phase II 32 Intensive (R-Hyper-CVAD/MA) Intensive (ASCT) 100% (CR/CRu: 81%) 78% (3 y) 97% (3 y) 
Geissler 2008 36  Phase II 159 Intensive (R-CHOP-HA) Intensive (ASCT) 96% (55%) 63% (4 y) 81% (4 y) 
View Large